Persistent infections and their relationship with selected oncologic and non-tumor pathologies

Figures & data

Table 1.  Presence of anti-hepatitis C virus (HCV) serum antibodies in individuals in the indicated populations.

Groups of observed persons	Persons with anti-HCV antibodies
	Total^a	Men^a	Women^a
Blood donors (n = 41,021; ♂ = 28,990; ♀ = 12,031)	1417 (3.45)	1145 (3.95)	272 (2.26)
Cleanup workers (n = 965; ♂ = 791; ♀ = 174)	^#218 (22.59)	^#169 (21.36)	^#49 (28.16)
Convalescents of ARS (n = 114; ♂ = 106; ♀ = 8)	^#31 (27.19)	^#28 (26.41)	^#3 (37.5)
Dwellers of radiation-contaminated area (n = 578; ♂ = 273; ♀ = 305)	^#65 (11.24)	^#37 (13.55)	^#28 (9.18)
NPP workers (n = 87; ♂ = 64; ♀ = 23)	^#22 (25.28)	^#19 (29.68)	^#3 (13.04)

^aFirst value given is actual number of subjects with the antibodies; value in parenthesis is the calculated percentage among the respective population analyzed.

^#Reported value was significantly different (P < 0.0001) from that in the blood donor (i.e., IR-non-exposed) persons.

Figure 1.  The frequency of some somatic disease in cleanup workers as related to hepatitis C virus (HCV) seropositivity. I: coronary heart disease, II: acute myocardial infarction in anamnesis; III: essential hypertension; IV: thyroiditis/goiter; V: type 1 diabetes; VI: type 2 diabetes/impaired glucose tolerance; VII: chronic hepatitis; VIII: chronic gastritis. Differences between HCV⁺ and HCV⁻ patients are significant at P < 0.05 (white star) or P < 0.001 (black star).

Table 2.   Presence of anti-cytomegalovirus (CMV) IgG serum antibodies in individuals in the indicated populations.

Groups of observed persons	Persons with anti-CMV antibodies
	Total^a	Men^a	Women^a
IR-non-exposed persons (n = 367; ♂ = 162; ♀ = 205)	254 (69.2)	114 (70.37)	140 (68.29)
Cleanup workers (n = 505; ♂ = 428; ♀ = 77)	^#401 (79.4) P < 0.001	^#342 (79.9) P < 0.01	^#59 (76.62) P < 0.05
Convalescents of ARS (n = 118; ♂ = 113; ♀ = 5)	^#101 (85.59) P < 0.001	^#96 (84.95) P < 0.004	5 (100)
Dwellers of radiation-contaminated areas (n = 115; ♂ = 61; ♀ = 54)	89 (77.39)	48 (78.68)	41 (7.92)
NPP workers (n = 122; ♂ = 98; ♀ = 24)	^#98 (80.32) P < 0.01	^#80 (81.63) P < 0.05	18 (75)

^aFirst value given is actual number of subjects with the antibodies; value in parenthesis is the calculated percentage among the respective population analyzed.

^#Reported value was significantly different (at indicated P value) from that in the IR-non-exposed group.

Figure 2.   The frequency of some somatic diseases in the observed patients appears to depend on cytomegalovirus (CMV) seropositivity. Group I = IR-non-exposed persons (Ia: CMV⁺, Ib: CMV⁻); Group II = cleanup workers (IIa: CMV⁺, IIb: CMV⁻); and Group III = ARS convalescents (IIIa: CMV⁺, IIIb: CMV⁻). Differences between CMV⁺ and CMV⁻ patients are significant at P < 0.05 (white star) or P < 0.001 (black star).

Table 3.  Ukrainian chronic lymphocytic leukemia (CLL) cases showing HCDR3 homology with immunoglobulins (Igs) of known specificity.

IgHV gene	HCDR3 Amino acid sequence	Subset	Antigen specificity
3-30-3*01_2-2*01_6*02_UM_AY909636	-EVQDIVVVPAAI–YYYYYGMDV		Anti-PPS Ig
UA1-69*01_2-2*01_6*02_UM_D70_EF583683	-G-GDIVVVPAEY–YYYYYGMDV	3^*
UA1-69*01_2-2*01_6*02_UM_D94_EF091906	PGPQDIVVVPAAY–YYYYYGMDV	3
UA1-69*01_2-2*01_6*02_UM_D3_EF175390	-EVQDIVVVPAAI–YYYYYGMDV	3
UA1-69*01_2-2*01_6*02_UM_C17_EF175388	-EVQDIVVVPAAI–YYYYYGMDV	3
UA1-69*01_2-2*01_6*01_UM_E94_EF175420	-EVQDIVVVPAAI–YYYYYGMDV	3
UA1-69*01_2-2*01_6*01_UM_F89_EU433873	-EVQDIVVVPAAI–YYYYYGMDV	3
3-33*01_3-3*01_4*02_UM_DQ535056	AG-SD-YDFWSGYPYYFDY		Anti-PPS Ig
UA4-30-4*01_3-3*01_4*01_UM_E16_EF583678	VGPSGYYDFWSGYPYYFDY	Het^‡
3-48*03_2-21*01_4*02_UM_AY909680	DRTYCGGDCYGPYFDY		Anti-PPS Ig
UA3-48*03_2-21*02_4*02_M_D76_EU814967	DVAYCGGDCYSGFFDY	Het
3-33*01_3-10*01_4*02_UM_DQ322780	PQLWFGELN-YYFDY		Anti-PPS human antibodies
UA3-11*01_3-10*01_4*02_UM_F85_EU433870	DTLWFGEFHAYYFDY	UA Ref13#
3-11*03_3-3*01_5*02_UM_DQ322854	DTRPYDFWSGYYP-NWFDP		Anti-PPS Ig
UA3-11*01_3-3*01_5*02_UM_G17_EU667604	–DRYDFWSGYIGYNWFDP	UA5#
UA4-61*01_3-3*01_5*02_UM_E53_EF091926	HRGDYDFWSGYYPYNWFDP	UA5
1-18*01_3-22*01_6*01_M_AF115133	–ADYYDSSGYYY-DYYYYGMDV		Anti-Neisseria meningitides Ig
UA4-4*02_3-22*01_6*02_UM_D36_EF583668	ASGNYYDSSGYYYWNYYYYGMDV	N7^**
UA3-11*01_3-22*01_6*03_UM_F34_EF175439	APKNYYDSSGYYYWNYYYYYMDV	N7
UA4-59*08_3-22*01_6*02_UM_D15_EU814956	–RPLYDSSGYYYVMNYYYGMDV	N7
3-30-3*01_3-22*01_4*02_UM_AB021532	AR-NYYDSSGY-SFDY		Anti-staphylococcal protein A Ig
UA4-59*01_3-22*01_4*02_UM_F35_EF175440	AR-YYYDSSGY-YFDY	33
UA4-b*01_3-22*01_4*01_UM_E99_EF175423	VKEYYYDSSGYYGFDY	33
3-30*03_2-8*02_6*02_UM_EF177969	DHRYCTGGVCYDGYYYYGMDV		Rotavirus-specific Ig
UA1-2*04_2-8*01_6*02_UM_F74_EU433868	PSFYCTNGVCYTDYYYYGMDV	Het
UA1-2*02_1-26*01_6*02_UM_AY944713	VYSGSYPYYYYGMDV		Rotavirus-specific Ig
UA1-2*02_1-26*01_6*02_UM_E70_EF091912	PYSGSYPWYYYGMDV	28
UA1-2*02_nd*01_6*02_UM_G19_EU667602	LYSGSYFYYYYGMDV	28
3-23*04_5-5*01_6*02_UM_AY944710	–ADTAMVIYYYYYGMDV		Rotavirus-specific Ig
UA3-43*01_5-5*01_6*02_UM_F24_EF407840	GMVDTAMVIYYYYYGMDV	Het
1-24*01_5-24*01_6*02_M_ Y17784	MKDGYNKVYYYYYGMDV		Anti-herpes simplex Ig
UA1-69*13_5-24*01_6*02_UM_GU358657	EGDGYNYGYYYYYGMDV	Het
1-69*06_3-16*02_3*02_UM_AF460965	GGNYDYIWGSYRSNDAFDI		Anti-cardiolipin Ig
UA1-69*01_3-16*02_3*02_UM_D34_EU814958	GGDYDYIWGSYRPNDAFDI	6
UA1-69*01_3-16*02_3*02_UM_E77_EF091909	GGDYDYIWGSYRPNDAFDI	6
UA1-69*01_3-16*02_3*02_UM_D89_EU814960	GGAYDYIWGSYRPNDAFDI	6
UA1-69*01_3-16*02_3*02_UM_D73_EF175395	GGGYDYIWGSYRSNDAFDI	6
1-3*01_3-10*01_3*02_M_AY393651	ASGRFWQSRG-DAFDI		Rheumatoid arthritis Ig
UA3-21*01_3-22*01_3*02_M_B78_EF175385	VSGRNYDSSGTDAFDI	Het
1-69*06_6-6*01_4*02_M_AY393692	GQGSSSSRFPFDY		Rheumatoid arthritis Ig
UA3-74*01_6-6*01_4*02_M_E22_EF441750	EEGSSSLR-PFDY	Het
5-51*03_6-13*01_4*02_UM_AY393191	RADTSSWYYFDY		Rheumatoid arthritis Ig
UA4-34*01_6-13*01_4*02_M_E49_EF441754	GGDGSSWYYFDF	UA Ref1#
4-34*01_3-3*01_4*02_UM_X54441	GGSV-LRFLEWLLYPAFDY		Rheumatoid arthritis Ig
UA1-69*06_3-3*01_4*02_UM_G12_EU667599	SGE–LRFLEWLLSADFDY	UA7#
UA1-69*01_3-3*01_4*02_UM_F10_EF175428	EGSRPLRFLEWLL–-FDY	UA7
1-69*13_2-2*01_6-13*01_UM_U86795	TDIVVVPAAMIIYYYYGMDV		Autoantibody activity
UA1-69*01_6-13_6*02_UM_E41_EF175412	VQGGSAAAYENYYYYYGMDV	UA Ref2#
UA1-69*01_2-2*01_6*01_UM_F3_EF175425	TLIGVPAAYTIYYYYYGMDV	UA Ref2
4-31*03_3-9*01_6*02_UM_U80127	DGGN–YDILTGYYRADYYYGMDV		BMT recipient with GVHD
UA3-21*01_3-9*01_6*02_UM_E85_EF407825	DGGSLYYDILTGYYSLEYYYGMDV	Het
1-18*01_2-15*01_4*02_M_X15611	APGYCSGGGCYRGDDY		B-cell lymphoma secreting anti-Pr2 erythrocyte autoantibodies
UA4-34*01_2-15*01_6*02_M_F20_EF583679	GSGYCSGGSCYGGLDV	UA Ref9#
AY942901	DFEYYYESSGY–-PYYYYGMDV		Anti-rabies Ig
3-33*01_3-22*01_6*02_UM_Z46379	DN-YYYDSSGY–-YYYYYGMDV		Anti-Sm Ig
UA1-2*04_3-22*01_6*02_UM_G2_EU433881	DLGHYYDSSGYSYPYYYYYGMDV	UA8#
UA3-30-3*01_3-22*01_6*02_UM_E73_EF175415	DTTYYYDSSGY–-YYYYYGMDV	UA8
UA4-59*01_3-22*01_6*02_UM_D62_EF091925	GVGDYYDSSGY–-LHYYYGMDV	UA8
3-49*04_3-3*01_6*02_UM_AY941852	DRDGTYYDFWSGYPPPNYGMDV		Anti-rabies Ig
UA1-69*01_3-3*01_6*02_UM_E92_EF583675	DWGTTYYDFWSGYFSP-YGMDV	Het
3-23*01_4-17*01_3*02_UM_AJ305181	GDYGDYSFAFDI		Anti-Sm Ig
UA3-33*01_4-17*01_3*02_UM_E13_EF407846	GVPGDYVMAFDI	UA9#
UA3-30-3*01_4-17*01_2*02_UM_F42_EF407832	GPRGDYVSSFDL	UA9

*Subset nomenclature according to Stamatopoulous et al. (2007) and Murray et al. (2008).

**New subsets according to Bomben et al. (2009).

^#New subsets according to Bilous et al. (2010).

^‡Het = heterologous sequences.

Murray, F., Darzentas, N., Hadzidimitriou, A., Tobin, G., Boudioora, M., Scielzo, C., Laoutaris, N., Karlsson, K., Baran-Marzsak, F., Tsaftaris, A., Moreno, C., Anagnostopoulos, A., Caligaris-Cappio, F., Vaur, D., Ouzonis, C., Belessi, C., Ghia, P., Davi, F., Rosenquist, R., and Smatatopoulos, K. 2008. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: Implications for the role of antigen selection in leukemogenesis. Blood 111:1524–1533.

 PubMed Web of Science ®Google Scholar

Bomben, R., Dal, B. M., Capello, D., Forconi, F., Maffei, R., Laurenti, L., Rossi, D., Del Principe, M. I., Zucchetto, A., Bertoni, F., Rossi, F. M., Bulian, P., Cattarossi, I., Ilariucci, F., Sozzi, E., Spina, V., Zucca, E., Degan, M., Lauria, F., Del Poeta, G., Efremov, D. G., Marasca, R., Gaidano, G., and Gattei, V. 2009. Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors: Results from an Italian multicentre study. Br. J. Haematol. 144:492–506.

 PubMed Web of Science ®Google Scholar

Bilous, N., Bomben R., Dal Bo, M., Capello, D., Forconi, F., Laurenti, L., Bertoni, F., Efremov, D. G., Marasca, R., Del Poeta, G., Martina Z., Kryachouk I., Dyagil, I., Gaidano, G., Chumak, A., Gattei, V., and Abramenko I. 2010. Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in an Ukrainian cohort. Leukemia Lymphoma 51:822–838.

 PubMed Web of Science ®Google Scholar